A study of activation of the cytokine network by interleukin 2, IL-2, may provide a rationale for devising cytokine combination and cytokine antagonist treatments with increased anti-tumour efficacy and decreased toxicity. We have investigated the expression of mRNA for 13 cytokines and three transcription factors during in vitro culture of peripheral blood mononuclear cells, PBMC, with IL-2. A consistent pattern of induction was seen in nine individuals, with early (2-24 h) induction of IL-1p, IL-6, tumour necrosis factor,
Therapy with IL-2, with or without ex vivo activated lymphocytes, has resulted in partial, and occasionally complete, tumour regressions in a minority of patients with melanoma and renal cell carcinoma (Dutcher et al., 1989; Negrier et al., 1990) . The induction of cytolytic activity in peripheral blood mononuclear cells, PBMCs, by IL-2 has been well documented both in vitro and in vivo (Grimm et al., 1982; Rosenberg et al., 1985) . The mechanisms of activation of this heterogeneous population of cells are not fully elucidated.
Several studies have shown that in vitro activation results in production of several cytokines. Early (24h) induction of IL-la and IL-1B mRNA has been reported, as has the induction of TNF, LT and IFN-7 mRNA (Kovacs et al., 1989) . In other studies mRNA for GM-CSF and IL-6 was detected in PBMC after 3 days of culture with IL-2 (Belldegrun et al., 1989; Kasid et al., 1989) .
The study of cytokines induced by IL-2 in vitro and in vivo is important for several reasons. First, these secretory products may contribute to the antitumour effects of IL-2 in vivo. Cytokines such as TNF and IFN-y have well documented antitumour activity in animal models (Kelly et al., 1989) , and synergy between IL-2 and other cytokines has been reported (Truitt et al., 1989) . Second, the toxicity of IL-2 therapy may be related to the cytokines released by activated PBMC. For instance, anti-TNF antibody abrogated some of the toxic side effects of IL-2 in tumour bearing mice (Fraker et al., 1989) , and antibodies to IL-S abolished the IL-2 induced eosinophilia in mice (Yamaguchi et al., 1990) . Third, studies of cytokine induction in a mixed population of mononuclear cells also gives us indications of the range of cytokines which may be induced after other mitogenic or antigenic stimuli.
In order to understand the potential of other cytokines or their antagonists, for influencing the anti-tumour activity or toxicity of IL-2 in humans, we have studied in detail the range and temporal sequence of cytokine mRNA and proteins induced by IL-2, and the producer cells of those cytokines. In this paper we present data obtained in in vitro cultures of human PBMC with IL-2.
Materials and methods

Reagents
Human rIL-2 was generously supplied by Glaxo IBM (Geneva, Switzerland) (specific activity 3.1 x 106U mg-'), Correspondence: F.R. Balkwill.
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and Roussel-UCLAF Centre de Recherche (Romaine, France) (specific actitivity 106 U mg-'). Maximum cytotoxicity was induced when the cells were cultured with 000 U mg-' of IL-2.
Preparation of PBMCs
Peripheral blood mononuclear cells from healthy donors were separated from heparinised venous blood on FicollHypaque gradient (Lymphoprep TM, Nycomed Pharma AS, Oslo, Norway). The cells were resuspended at 1 x 106 ml-' in RPMI 1640 containing 10% heat inactivated foetal calf serum with or without 1000 U ml rhIL-2. Cellular cytotoxicity was assayed after 3 days of culture. For northern blot analysis cells were lysed with guanidine-isothiocyanate solution for RNA extraction. For in situ hybridisation cells were immunostained for FACS sorting.
Cell lines as positive controls for Northern blot analysis The HL60 human promyelocytic leukaemic cell line was maintained in 5% FCS/RPMI 1640. Total cellular RNA was extracted after a 3 h incubation with 50 ng ml-l PMA (Sigma, Dorset, UK) . This constituted a source of TNF, IL-lo, IL-1p, M-CSF, and TGF-P mRNA as a positive control for Northern blot analysis. Human T-cell line Jurkat cells were stimulated overnight with 1 ng ml-' phytohaemagglutinin (Sigma, Dorset, UK) and 20 ng ml-' PMA. Extracted RNA provided a positive control for IFN-'y. Human foreskin fibroblasts were stimulated with 10 ng ml-' PMA for 1 h, providing a positive control for IL-6 mRNA. MLA-144 T cell line stimulated with PHA and PMA provided a positive control for GM-CSF mRNA. It was not possible to obtain reliable controls for IFN-a and IL-4 expression using Northern analysis however the INF-a factor reacted on a Southern blot.
Labelling of target cells
Freshly thawed T 24 cells were washed three times in complete medium. 0.1 mCi of 5"Cr (Na251CrO4) (Amersham International UK) was added to the cell pellet. Cells were incubated at 37°C for 1 h, then washed in complete medium three times to remove unbound 5"Cr. Cells were resuspended in medium at a final concentration of 5 x 104 ml-'.
Isolation of cellular RNA Non-adherent cells from PBMC cultures were harvested. The adherent cells were scraped with rubber policeman into guanidine-isothiocyanate solution which was then used to lyse the non-adherent fraction. Total cellular RNA was isolated after centrifugation through cesium chloride followed by precipitation with 3 M sodium acetate and ethanol (Chirgwin et al., 1979 
Probes
For Northern analysis The following probes were used: TNF: PstI fragment of p-hTNF 1; IFN-y: BamHI fragment of pBR327gO-2; IL-la: HindIII-EcoRI fragment of pSPhILla.2; IL-lb: HindIII fragment of pSPhL-1P.2; IL-6: BglII fragment of pSP65T-IL-6; TGF-Pxw EcoRI fragment pbas TGF-P1 (Genentech, California); P-actin: EcoRI-Hindlll fragment of M 13 P-actin; IL-5: XbaI-BamHI fragment of pGEM4 IL-5; M-CSF: PstI-SmaI fragment of pUC18 M-CSF; GM-CSF: HXhI fragment of pXM GM-CSF; Gro: geneEcoRI fragment of pGEM3 Gro; IFN-oa: EcoRI fragment of PIF 21 1-hIFN-a2 (Wellcome, Beckenam, Kent, UK); LT-HindIII-PVUII fragment of pOKBLT-6-hLT; IL-10: cDNA clone (Vieira et al., 1991) . c-myc: BamHI-SalI fragment of DOR h-c-myc; c-jun: EcoRI-BamHI fragment of M13 c-jun; fos: BglI-PvuII fragment of pFBH-1-fos; ras:
EcoRI fragment of pBR322 ras-Ha (Dhar et al., 1982) .
For in situ hybridisation An antisense P-actin riboprobe was generated from HindIII cleaved Bluescript M13 IB-actin using T7 RNA polymerase. This was used as a positive controls in all runs. Antisense TNF was generated from the ApaI cleaved pGEMI-hTNF using T7 RNA polymerase (Promega Biotech, Madison WI). The negative control was sense TNF generated from BamHI cleaved pGEM-hTNF using Sp6 RNA polymerase (Promega, Biotech). The antisense IFN-y riboprobe was generated from ApaI cleaved pGEM-3 using T7 polymerase, the sense control was generated from EcoRI cleaved pGEM-3 using Sp6 polymerase. Antisense IL-1p riboprobe was generated from EcoRI linearised pSP h IL-1-P.2 Antisense IL-6 riboprobe was generated from AccI linearised pGEM-3 using T7 polymerase, sense control from XbaI linearised pGEM-3 using Sp6 polymerase. In vitro transcriptions were performed using Promega Biotech transcription kits to incorporate 3"S-UTP (Amersham International Cytokine protein assays IL-1p--was measured using EASIA kit from Medgenix (Brussels, Belgium) with a range of 33-1400 pg ml-'. It was standardised against an international reference preparation (86/680) from the National Institute of Biological Standards and Controls, NIBSC, and was used at detection limits of 33 pg ml'. TNF-o and IFN-y were measured using IRMA kits from Medgenix (Brussels, Belgium). The TNF-a IRMA range was from 15-5000 pg ml-'. It was standardised against an international reference preparation (87/650) from the National Institute of Biological Standa'rds and Controls, NIBSC, and was used at detection limits of 30 pg ml-'. The IFN-y-IRMA range was from 0-90 U ml-'. It was standardised against an international reference preparation (88/606) from NIBSC and was used at detection limits of 2.5 U ml-'.
The IFN-a was measured using RIA kits from Medgenix (Brussels, Belgium). The range was from 0-200 U ml-'. It was standardised against an international reference preparation (82/576) from NIBSC and was used at detection limits of 8.0 U ml'. IL-6 was an 'in house' RIA (antisera G150 BM from Dr S. Poole, NIBSC). The antisera was used at a final dilution of 1:1,750,000 (equivalent to an initial dilution of 1:350,000). The assay was standardised against an international reference preparation (88/514) from -NIBSC and was used at detection limits of 70 pg ml-'.
Results
Induction of cytokine and proto-oncogene mRNA in IL-2 stimulated cultures-Northern analysis
In the first series of experiments we studied the induction of mRNA for 13 different cytokines in PBMC stimulated with 10,000 U ml-' IL-2, a concentration of IL-2 that generated maximal in vitro cytotoxicity against T24 cells. Table I and Figure 1 show the results obtained in cultures from one normal individual. In the interests of clarity, Table I only shows the mRNA induction in IL-2 stimulated cultures. The figure, however, clearly shows that there was no appreciable induction of cytokine mRNA in the cultures without IL-2. In this first individual, there were three different patterns of cytokine induction: TNF and LT were detected as early as 
Exp. no. 1 (h = hour, d = day) (+) indicates the intensity of mRNA induction within each individual case. In this experiment, all time points were studied without IL-2 but only one representative time point is shown as (C).
throughout the 7 days of culture; IL-1,, IL-6 and the gro gene (a member of the intercrine family, related to IL-8) were also induced 2 h after stimulation, but their induction was only transient, and none of these were detected after 3 days of culture; IL-5, IFN-'y, GM-CSF, and M-CSF were induced at a later time, being first present at 2-3 days. Expression was then sustained throughout the culture period in all of these except M-CSF. mRNA for IFN-a, IL-la, and IL-4 were not detected during this time. TGF-P mRNA was present in all cultures, stimulated or unstimulated (data not shown).
This pattern of cytokine gene expression during culture of PBMC with IL-2 was found to be reasonably consistent in PBMC from another eight individuals who were studied (Table II) . TNF and IL-lp were induced in PBMC from 8/8 individuals, LT, gro, IL-6, GM-CSF, IFN-y and M-CSF were induced in 4/4 studied. IL-5 mRNA was only detectable in PBMC from 1/4 individuals studied but was also expressed in the unstimulated culture from that individual, and IFN-x and IL-4 were again not found. A probe for IL-10 was also included in this series. In one individual IL-10 mRNA was induced in unstimulated cells after 24 h of culture. The intensity of the message started to decline during the first 2 days of culture with IL-2 and was not detected at later time points (Figure 2) . Identification of cells producing the cytokine mRNA Using FACS sorting and in situ hybridisation with cytokine riboprobes, we identified the producer cells of four different cytokines, TNF, IL-1p, IFN-y, and IL-6 in the total population and the sorted cells. These cytokines were studied at the time of peak message induction in the Northern blots, in three individuals. The proportion of cells in the total population with detectable cytokine mRNA ranged from 2-16% after 1 day of culture for IL-6 and IL-1,B, and 4 days of culture for IFN-y and TNF. As a control for cytokine mRNA stability during FACS sorting, the total PBMC population was passed through the sorting process and the percentage of cells expressing cytokine mRNA compared to that in cells cytospun at the beginning of this process. No differences were seen. Because of the small numbers of cells involved in these experiments, the gated populations were resorted to ensure high degrees of purity. Resorting of cells likewise did not affect mRNA stability.
IL-Jp In two of the three individuals, 2-3% cells in the total population expressed IL-1p mRNA. These cells were monocytes, and in sorted populations 8-35% of monocytes expressed IL-l1 mRNA. In cells from a third individual, IL-1lB mRNA was induced in 19% of monocytes, 6.6% of NK cells, 3% CD4 + and 8% CD8 + cells on IL-2 stimulation, making a total of 16% expressing cells in the total population. In the unstimulated control cultures a small proportion of monocytes and CD8 + cells expressed IL-1p mRNA (0.1-0.5% and 0.2% of the total population respectively).
IL-6 In the three individuals 0.4-6% of the total cells expressed IL-6 mRNA after 24 h stimulation with IL-2. In two out of three cases IL-6 mRNA was detected in the monocyte (2-6% monocytes positive) and NK (1-4% cells positive) populations. In the third case IL-6 mRNA was detected only in monocytes (22% positive). IFN-7 Between 2 and 5% of the total cell population expressed IFN-y mRNA. IFN-y mRNA was detected in all sorted populations except the CD8 cells. NK (6-13% cells positive) and CD4 cells (2-3% positive) made a significant contribution to levels of mRNA in the total population, but, 
IL-1p
The production of IL-1p in the IL-2 stimulated cultures was maximal in the first 2 days of culture. The IL-lp concentration varied from 90 pg ml-' to 1300 pg ml-'. In unstimulated cultures it peaked at lOOpgml-'.
IL-6 IL-6 protein concentration peaked maximally after 2-4 days of culture with IL-2, occurring after the first evidence of IL-6 mRNA induction. In one of seven unstimulated cultures, the spontaneous production of IL-6 protein was at a level (3029pgml-') comparable to the IL-2 stimulated culture. In the other unstimulated cultures IL-6 concentration ranged between 0-1206. After IL-2 stimulation, the maximal concentration ranged from 2903-3512 pg ml'.
IFN-y Maximal production of IFN-y protein by IL-2 stimulated PBMC was invariably found at 4 days of culture. The maximum IFN-y concentration varied from 28-90IUml1'. No spontaneous production was detected in the unstimulated culture supernatants. The pattern of protein production matched exactly IFN-y mRNA induction.
TNF Maximum levels of TNF were detected at 4 days of culture, in seven experiments and at 7 days in one experiment. Spontaneous production occurred one out of six cultures (1100 pg ml-'). The TNF concentration in control cultures was 30-1100 pg ml-', while maximal production on IL-2 stimulation ranged between 5,300-10,000pgml-'. In at least four of the cytokines, TNF, IL-1p, IFN-y and IL-6, the production of the protein mirrored the expression of mRNA. Previous in vitro studies reported the production of Il-lm and P proteins in culture supernatants of II-2 stimulated PBMC (Numerof et al., 1989) . In situ hybridisation studies on FACS sorted PBMC revealed that the monocytes were the main producers of the above mentioned cytokines, but the NK cells shared in the production of IL-6 and IFN-y, while the CD4 + cells produced IFN-y as well. At each given time point only a small percentage of cells in The total or in the sorted population was positive for each cytokine mRNA. This low figure may influence any firm conclusions as to the cellular source of the cytokines. However, each gated population was resorted in each experiment, and this resulted in high (<95%) purity. We do not think the low level of positivity is due to limits of detection of this technique because a high percentage of positive cells was seen in controls incorporated in each experiment. PMA induced HL60 cells were used as positive controls for TNF, IL-P and IFN-y mRNA, PMA induced HFF cells were used for IL-6 mRNA induction. More than 90% of cells counted were positive for the relevant mRNA. In addition, control experiments proved that the low percentage was not due to instability of RNA during the sorting process, as described in the Results section.
The production of cytokines by the monocytes is unlikely to be due to a direct effect of IL-2 on the monocytes. These cells express the IL-2Ra subunit of the I1-2 receptor only when activated (Waldmann, 1991) . It is more likely that an intermediary molecule, possibly one of the other cytokines induced early on, is responsible for the monocyte cytokine production. A more detailed study using in situ hybridisation at earlier time points would be of interest, as would study of in situ production of some of the other cytokine mRNAs identified in the Northern blots. The expression by monocytes of mRNA for one of the cytokines, IFN-y, is not, to our knowledge a common finding, although murine macrophages have been reported to produce IFN-y after stimulation with polyinosinic-polycytidilic acid (Djeu et al., 1979) . The beta chain of the IL-2 receptor is expressed on 90% freshly isolated monocytes (Espinoza-Delgado et al., 1990) , but the alpha chain only on IFN-y activation (Waldmann, 1991) . This again suggests that intermediatory cytokines, or other factors, produced by lymphocytes, act as a stimulus for IFN-y mRNA expression in these cultures. It is not however certain whether monocytes in the cultures can produce IFN-y protein.
We are currently investigating this. Early induction of the cytokines by IL-2 suggests that they might share in the generation of cytolytic activity of PBMC, particularly as certain cytokines when added exogenously to culture, have been found to synergise with IL-2. TNF enhanced the cytolytic function in PBMC by IL-2, possibly through the induction of high affinity IL-2 receptor complex (Blay et al., 1989) , and high serum levels of TNF have been correlated with response to therapy in one clinical study (Blay et al., 1990) .
The production of IFN-y by IL-2 stimulated PBMC in vivo might induce the expression of class I MHC antigen on tumours thus assisting the CTL cytolytic function (Dustin et al., 1986) . This function might be helped by TNF which induces the expression of the same antigen (Weber & Rosenberg, 1990) . IFN-y might also induce tumour antigen on tumour cells thus helping the non-MHC restricted cytotoxicity (Imai et al., 1981) .
IL-lp was detected in supernatants of IL-2 stimulated PBMC, and its exogenous addition to the culture synergised with IL-2 (Crump et al., 1989) . IL-lp exerts a cytotoxic effect on its own (Gaffney & Tsai, 1986) . It was found to induce gro gene a finding that was specifically associated with the anti-mitogenic effect of IL-1 (Rangnekar et al., 1991) . Gro gene mRNA was detected in PBMC early in culture with IL-2. It might be IL-1 induced, and may as well share in the cytotoxic activity.
IL-6 also synergises with IL-2 stimulating PBMC (Gallagher et al., 1990) . It was found to enhance of pore forming protein gene expression, and is essential, and is essential for the cytolytic T cell function in humans (Smyth et al., 1990; Galandrini et al., 1991) . IL-6 was found to have antiumour activity in tumour bearing mice (Mule et al., 1990) .
In a murine model IL-5 enhanced IL-2 induced cytolytic activity in murine splenocytes (Aoki et al., 1989) . While in humans, the eosinophilia observed in patients receiving IL-2 therapy might very well be related to the production of IL-5.
In the murine model mRNA expression of IL-5 in IL-2 stimulated murine splenocytes both in vivo and in vitro corresponded with the occurrence of eosinophilia (Yamaguchi et al., 1990) . Pisani et al. (1991) measured IL-5 levels in serum of patients treated with IL-2 and reported the elevation of serum concentration of IL-5. In another study intrapleural administration of IL-2 in patients with malignant effusion resulted in an influx of eosinophils (Nakamura et al., 1990) .
The cause of IL-2 induced toxicity remains unknown. The most significant problems are cardiovascular with hypotension, renal failure, fluid retention and a capillary leak syndrome. It has been suggested that TNF and IFN-y contribute to the toxic effects (Kohler & Sondel, 1989) . Passive immunisation against TNF by antibodies increased the number of doses of IL-2 that could be given to mice before fatal toxicity (Fraker et al., 1989) .
C-fos and c-myc genes and their relevant proteins, exert a role in cellular activation (Kaczmarek & Kaminiska, 1989) and together with c-jun are part of the regulatory network of gene expression (Bertani et al., 1989) . The induction of cytokine mRNA may be dependent on the induction of these genes and their relevant proteins. We are currently studying the role of protein synthesis in these effects.
The detection of IL-10 (cytokine synthesis inhibitory factor) mRNA in one of the cases suggests an autoregulatory function. IL-lO mRNA was expressed in unstimulated PBMC and declined in IL-2 stimulated PBMC. IL-10 downregulates the induction of other cytokines (IL-1, IL-6, IL-8, TNF, GM-CSF, G-CSF) and exerts an autoregulatory function on its mRNA induction in LPS stimulated monocytes (De WaalMalefyt, 1991) .
Recent clinical studies have suggested that this simple in vitro model may help in understanding the activation of the cytokine network in patients treated with IL-2, and in designing trials with cytokine combinations. For instance, List et al. (1992) found transient induction of TNF, IL-lp, and IFN-'y in the cerebrospinal fluid of patients receiving IL-2 by the intraventricular route. In other clinical studies, blood from IL-2 treated patients has been reported to contain IL-6, TNF and IFN-y (Schaafsma et al., 1991; Boccoli et al., 1990) and using PCR mRNA for M-CSF, GM-CSF, IL-3, and IL-5 was detected in PBMC form IL-2 treated patients (Schaafsma et al., 1991) . The sequence of release of these cytokines resembled that seen in cultured PBMC, with the exception of IFN-y which was released earlier in vitro compared with in vivo (e.g. List et al.) . However, it is probable that other cell populations may be able to respond to IL-2 or cytokines induced during its use in vivo. Although IL-2 receptor expression is thought to be restricted primarily to haemopoietic cells, there are reports that some tumour cells will respond directly to IL-2 (Saachi et al., 1990) . Moreover, tumour cells may well respond to cytokines induced by IL-2 tumour infiltrating lymphocytes.
In summary, IL-2 induced the mRNA of ten cytokines in PBMC in vitro which might reflect the in vivo release of cytokines during IL-2 therapy. These cytokines are likely to contribute to the therapeutic and the toxic effects of IL-2 in patients. Studies such as these may help rationalise the use of submaximal doses of cytokines or specific cytokine inhibitors/ binding proteins to obtain a final combination with greater or equivalent therapeutic efficacy and less toxicity.
